Extendicare (TSE:EXE – Get Free Report) issued its earnings results on Thursday. The company reported C$0.29 EPS for the quarter, FiscalAI reports. The firm had revenue of C$462.03 million during the quarter. Extendicare had a net margin of 4.48% and a return on equity of 64.13%.
Extendicare Trading Down 1.4%
TSE:EXE opened at C$24.15 on Friday. The company has a market capitalization of C$2.28 billion, a PE ratio of 22.78 and a beta of 1.30. Extendicare has a 52-week low of C$11.59 and a 52-week high of C$25.67. The stock’s 50 day moving average price is C$22.99 and its 200 day moving average price is C$18.64. The company has a quick ratio of 0.98, a current ratio of 0.62 and a debt-to-equity ratio of 283.02.
Analyst Ratings Changes
A number of brokerages have issued reports on EXE. TD Securities lifted their price target on Extendicare from C$15.00 to C$19.00 in a report on Thursday, November 13th. Canaccord Genuity Group raised their target price on Extendicare from C$20.00 to C$22.50 in a research report on Thursday, December 4th. Cormark upped their price target on Extendicare from C$25.00 to C$30.00 in a report on Wednesday, December 3rd. National Bank Financial increased their price target on shares of Extendicare from C$24.50 to C$29.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Finally, Canadian Imperial Bank of Commerce boosted their price objective on shares of Extendicare from C$18.00 to C$22.00 in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of C$24.50.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
- Five stocks we like better than Extendicare
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
